drugset / Trial / NCT07168317
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL
NaSingle-groupOpen-labelTreatment
Summary
Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive lymphoma. At present, the treatment of new diagnosed AITL has limited efficacy and a high recurrence rate. The study seeks to explore the possibility of improving the efficacy of immunotherapy and chemotherapy and epigenetically regulated drugs.
Timeline
- Start
- 2025-08-01
- Primary completion
- 2028-08-01
- Completion
- 2028-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Subject | Mitoxantrone | Small molecule | 20 mg/m2 | — |
| Subject | Prednisone | Other / unclassified | 100 mg | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Tucidinostat | Small molecule | 20 mg | — |